

**IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

GLAXOSMITHKLINE LLC,
SMITHKLINE BEECHAM (CORK)
LIMITED,

Plaintiffs,

v.

TEVA PHARMACEUTICALS USA, INC.,

Defendant.

C. A. No. 14-878-LPS-CJB

PLAINTIFFS' NOTICE OF APPEAL

Notice is hereby given that Plaintiffs GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited (collectively, "Plaintiffs"), hereby appeal to the United States Court of Appeals for the Federal Circuit from the Order entering Final Judgment in this action entered on April 25, 2018 (D.I. 495), which among other things, granted Defendant Teva Pharmaceutical USA, Inc. ("Defendant") Final Judgment that Defendant did not induce infringement of the asserted claims of U.S. Patent No. RE40,000, and from any and all other adverse rulings, whether oral or written, that are incorporated in, antecedent to, or ancillary to the Final Judgment; and any and all adverse interlocutory orders, judgments, decrees, decisions, rulings, and opinions, whether oral or written, that merged into and become part of the Final Judgment, that shaped the Final Judgment, that are related to the Final Judgment, and upon which the Final Judgment is based; including, but not limited to, the Memorandum Opinion Regarding Pending Motions entered on March 28, 2018 (D.I. 489), the Order Re Memorandum Opinion entered on March 28, 2018 (D.I. 490), the Final Jury Instructions dated June 19, 2017 (D.I. 440), the Memorandum Order Re Report and Recommendation Re Summary Judgment of Induced Infringement (D.I. 411), the

Memorandum Order Re Report and Recommendation Re Convoyed Sales (D.I. 382), the Order Regarding Motions *In Limine* (D.I. 379), the Memorandum Order Re Report and Recommendation Re Claim Construction (D.I. 290), and any and all adverse interlocutory orders, judgments, decrees, decisions, rulings, opinions, and reports and recommendations, whether oral or written, that merged into and became part of each of these Orders.

A payment of \$505 representing the \$5 filing fee required by 28 U.S.C. § 1917 and the \$500 docketing fee required by Federal Circuit Rule 52(a)(3)(A) is transmitted via this Court's online payment system with this Notice of Cross Appeal, pursuant to Federal Rule of Appellate Procedure 3(e) and Federal Circuit Rule 52(a)(2).

Dated: May 14, 2018

FISH & RICHARDSON P.C.

By: /s/ Douglas E. McCann

Douglas E. McCann (#3852)
222 Delaware Avenue, 17th Floor
Wilmington, DE 19801
Tel.: (302) 652-5070
Fax: (302) 652-0607
dmccann@fr.com

OF COUNSEL:

Juanita R. Brooks
Jonathan E. Singer
Michael A. Amon
Craig E. Countryman
Robert M. Yeh
FISH & RICHARDSON P.C.
12390 El Camino Real
San Diego, CA 92130
Tel.: (858) 678-5070
Fax: (858) 678-5099
brooks@fr.com; singer@fr.com;
amon@fr.com; countryman@fr.com;
ryeh@fr.com

Michael J. Kane
William R. Woodford
Elizabeth M. Flanagan (DE #5891)
Phillip W. Goter
FISH & RICHARDSON P.C.
3200 RBC Plaza
60 South Sixth Street
Minneapolis, MN 55402
Tel: (612) 335-5070
Fax: (612) 288-9696
kane@fr.com; woodford@fr.com
eflanagan@fr.com, goter@fr.com

***Attorneys for Plaintiffs GlaxoSmithKline
and SmithKline Beecham (Cork) Limited***